Metallo-Thrapy markets in-vivo contrast agents based on its innovative modified gold nanoparticles (GNPs) for oncology research and early stage drug discovery.

Use of modified GNPs provides a precise cost effective imaging alternative to state-of-the-art cancer imaging modalities. High concentrations of GNPs in cancer tissues result in CT images with high Hounsfield unit (HU) numbers, close to those of high density tissues, e.g. bones. 

For details and price quotations contact This email address is being protected from spambots. You need JavaScript enabled to view it..




Metallo-Therapy: Gold nanoparticles for better cancer management
Copyright © 2016 Metallo-Therapy Ltd
Website by Sigalon